drugset / Trial / NCT00266331

RayGel-An Alternative for Skin Care During External Beam Radiation

NCT00266331

Phase 2 Completed 150 enrolled Nathalie Johnson
RandomizedParallel-groupTriple-blindPrevention

Summary

This study is for the patient with breast cancer. To take part in this study, external beam radiation therapy needs to be part of the treatment plan. Reduced glutathione, an ingredient of RayGel™, has been helpful in decreasing some radiation therapy side effects to the skin. Reduced glutathione plays a vital role in both making DNA and cell repair. This study will measure if RayGel decreases skin reaction in breast cancer patients treated with external beam radiation therapy.

Timeline

Start
2004-10
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator reduced glutathione Unknown Topical

Indications